<?xml version="1.0" encoding="UTF-8"?>
<sec id="sec4dot2-ijms-19-00686" class="sec">
 <div class="title" xmlns="http://www.w3.org/1999/xhtml">4.2. Oleuropein as Anticancer Agent</div>
 <p xmlns="http://www.w3.org/1999/xhtml">There are numerous studies confirming the anticancer activity of oleuropein, as observed in human cancer cell lines, such as: breast adenocarcinoma (cell line MCF-7, MDA) [
  <a rid="B83-ijms-19-00686" ref-type="bibr" href="#B83-ijms-19-00686">83</a>,
  <a rid="B84-ijms-19-00686" ref-type="bibr" href="#B84-ijms-19-00686">84</a>,
  <a rid="B85-ijms-19-00686" ref-type="bibr" href="#B85-ijms-19-00686">85</a>,
  <a rid="B86-ijms-19-00686" ref-type="bibr" href="#B86-ijms-19-00686">86</a>,
  <a rid="B87-ijms-19-00686" ref-type="bibr" href="#B87-ijms-19-00686">87</a>], melanoma (cell line RPMI 7951) [
  <a rid="B86-ijms-19-00686" ref-type="bibr" href="#B86-ijms-19-00686">86</a>], urinary bladder carcinoma (cell line T-24) [
  <a rid="B86-ijms-19-00686" ref-type="bibr" href="#B86-ijms-19-00686">86</a>], colorectal adenocarcinoma (cell line HT 29, Caco-2, LoVo) [
  <a rid="B86-ijms-19-00686" ref-type="bibr" href="#B86-ijms-19-00686">86</a>,
  <a rid="B88-ijms-19-00686" ref-type="bibr" href="#B88-ijms-19-00686">88</a>,
  <a rid="B89-ijms-19-00686" ref-type="bibr" href="#B89-ijms-19-00686">89</a>], prostate cancer (cell line TF1) [
  <a rid="B87-ijms-19-00686" ref-type="bibr" href="#B87-ijms-19-00686">87</a>], lung carcinoma (cell line A549) [
  <a rid="B90-ijms-19-00686" ref-type="bibr" href="#B90-ijms-19-00686">90</a>], glioblastoma (cell line LN 18), renal cell adenocarcinoma (cell line 786-O) [
  <a rid="B87-ijms-19-00686" ref-type="bibr" href="#B87-ijms-19-00686">87</a>], and glioma (cell line U251, A172) [
  <a rid="B91-ijms-19-00686" ref-type="bibr" href="#B91-ijms-19-00686">91</a>].
 </p>
 <p xmlns="http://www.w3.org/1999/xhtml">Oleuropein was found to display antiproliferative, proapoptotic effects [
  <a rid="B92-ijms-19-00686" ref-type="bibr" href="#B92-ijms-19-00686">92</a>], overall anticancer activity [
  <a rid="B93-ijms-19-00686" ref-type="bibr" href="#B93-ijms-19-00686">93</a>], and specifically an ability to decrease cancer cell viability [
  <a rid="B94-ijms-19-00686" ref-type="bibr" href="#B94-ijms-19-00686">94</a>], as well as induction of cancer cell apoptosis [
  <a rid="B95-ijms-19-00686" ref-type="bibr" href="#B95-ijms-19-00686">95</a>,
  <a rid="B96-ijms-19-00686" ref-type="bibr" href="#B96-ijms-19-00686">96</a>,
  <a rid="B97-ijms-19-00686" ref-type="bibr" href="#B97-ijms-19-00686">97</a>,
  <a rid="B98-ijms-19-00686" ref-type="bibr" href="#B98-ijms-19-00686">98</a>]. Oleuropein induces apoptosis in breast cancer cells (MCF-7) via the 
  <span class="italic">p53</span>-dependent pathway and through the regulation of 
  <span class="italic">Bax</span> and 
  <span class="italic">Bcl2</span> genes. Therefore, oleuropein may have a great therapeutic potential for breast cancer treatment [
  <a rid="B99-ijms-19-00686" ref-type="bibr" href="#B99-ijms-19-00686">99</a>]. Interestingly, oleuropein has been reported to inhibit aromatase, a cytochrome P450 enzyme, which is an important pharmacological target in breast cancer therapy [
  <a rid="B100-ijms-19-00686" ref-type="bibr" href="#B100-ijms-19-00686">100</a>]. Moreover, it increases cancer cell sensitivity to trastuzumab (&gt;1000-fold increase) in SKBR3/Tzb100 cell model of acquired resistance [
  <a rid="B62-ijms-19-00686" ref-type="bibr" href="#B62-ijms-19-00686">62</a>]. Studies in animal models have shown that oleuropein administration prevents breast cancer [
  <a rid="B87-ijms-19-00686" ref-type="bibr" href="#B87-ijms-19-00686">87</a>], skin cancer [
  <a rid="B101-ijms-19-00686" ref-type="bibr" href="#B101-ijms-19-00686">101</a>], and various soft tissue cancers [
  <a rid="B86-ijms-19-00686" ref-type="bibr" href="#B86-ijms-19-00686">86</a>]. 
 </p>
 <p xmlns="http://www.w3.org/1999/xhtml">Interestingly, oleuropein showed uroprotective effect against cyclophosphamide-induced hemorrhagic cystitis in a rat model mostly through its antioxidant and anti-inflammatory activities. [
  <a rid="B102-ijms-19-00686" ref-type="bibr" href="#B102-ijms-19-00686">102</a>]. Thus, it can be considered as a new anticancer compound for adjuvant therapy not only targeting different stages of cancer development, but also alleviating certain adverse effects in the course of cancer chemotherapy. With respect to the pronounced antioxidant properties of oleuropein, it protects cells from genetic damage, potentially leading to oncogenesis. Anti-angiogenic properties of oleuropein prevent or at least slow down tumor development [
  <a rid="B86-ijms-19-00686" ref-type="bibr" href="#B86-ijms-19-00686">86</a>].
 </p>
</sec>
